Cingulate Q3 EPS Reduced by Ascendiant Capital Markets

Cingulate Inc. (NASDAQ:CING) – Equities research analysts at Ascendiant Capital Markets reduced their Q3 2026 earnings per share estimates for Cingulate in a report issued on Wednesday, August 19th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($0.39) per share for the quarter, down from their prior estimate of ($0.33). Ascendiant Capital Markets has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($2.39) per share. Ascendiant Capital Markets also issued estimates for Cingulate’s Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.04) EPS, Q1 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.29) EPS and FY2027 earnings at ($1.38) EPS.

Several other research analysts have also weighed in on the stock. Roth Capital set a $9.00 price objective on shares of Cingulate and gave the stock a “buy” rating in a research note on Sunday. Wall Street Zen raised shares of Cingulate from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Cingulate in a report on Tuesday, May 26th. Finally, Weiss Ratings cut shares of Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cingulate has an average rating of “Moderate Buy” and an average price target of $27.00.

Cingulate Price Performance

Shares of NASDAQ:CING opened at $5.68 on Tuesday. The company has a market capitalization of $82.60 million, a price-to-earnings ratio of -1.58 and a beta of -0.90. The firm’s 50 day simple moving average is $4.99 and its 200 day simple moving average is $5.57. Cingulate has a fifty-two week low of $3.16 and a fifty-two week high of $11.89.

Cingulate (NASDAQ:CING) last issued its earnings results on Thursday, August 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.18.

Hedge Funds Weigh In On Cingulate

Several institutional investors have recently modified their holdings of CING. XTX Topco Ltd bought a new stake in Cingulate during the 4th quarter worth approximately $90,000. Quadrature Capital Ltd bought a new position in Cingulate in the fourth quarter valued at approximately $66,000. Kestra Advisory Services LLC lifted its stake in Cingulate by 29.8% in the fourth quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock valued at $529,000 after buying an additional 27,979 shares in the last quarter. DRW Securities LLC acquired a new position in shares of Cingulate in the fourth quarter valued at approximately $255,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Cingulate by 43.9% in the fourth quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock valued at $265,000 after buying an additional 18,629 shares during the period. Institutional investors own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.